10% Off $75 Orders! Use Code SAVE10P Shop Now
One use per customer. Not available with Autoship. Expires 5/28/18.

Abstract: Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome

1 Star2 Stars3 Stars4 Stars5 Stars (340 votes, average: 2.95 out of 5)
Loading...

In Vivo. 2005 Nov-Dec;19(6):1013-21.

Nijs J, De Meirleir K.

Department of Human Physiology, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium. Jo.Nijs@vub.ac.be

This paper provides an overview of the evidence addressing the impairments of the 2′-5′ oligoadenylate (2-5 A) synthetase/RNase L pathway in Chronic Fatigue Syndrome (CFS) patients. The 2-5A synthetase/RNase L pathway in CFS patients appears to be both up-regulated (i.e. increased levels of bioactive 2-5A synthetase and increased activity of the RNase L enzyme) and deregulated (elastase and calpain initiate 83 kDa RNase L proteolysis, generating two major fragments with molecular masses of 37 and 30 kDa, respectively).

The deregulation of the 2-5A synthetase/RNase L pathway in CFS accompanies decreased NK-function and deregulation of apoptotic pathways. Since various components of the pathway appear to be related to performance during a graded exercise stress test, some evidence supportive of the clinical importance of the impaired pathway in CFS patients has been provided. Studies addressing the treatment of the deregulation of the 2-5A synthetase/RNase L pathway in CFS are warranted.

PMID: 16277015 [PubMed – in process]

1 Star2 Stars3 Stars4 Stars5 Stars (340 votes, average: 2.95 out of 5)
Loading...



Leave a Reply